ClinicalTrials.gg
TerminatedNCT03947255Updated Oct 13, 2023Results posted

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

A Phase 2 interventional study of brentuximab vedotin in Hodgkin Lymphoma, Peripheral T Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Seagen Inc.. Terminated at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-13.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Why this study was terminated
Study stopped early due to low patient accrual.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
72nd of 80
12 · median 52
Started
2019
with 4 others
Phase 2
41 of 80
8 open now
Registered
64th of 80
by date
Lead sponsor
12 of 80
Seagen Inc.

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 72nd largest by enrollment, is one of 5 that started in 2019, is one of 41 in phase 2, and was the 64th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment.

Read the detailed description

This is a study to determine the safety and efficacy of brentuximab vedotin in subjects with classic Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T cell lymphoma (PTCL) who experienced complete response (CR) or partial response (PR) with a brentuximab vedotin-containing regimen and subsequently experienced disease progression or relapse.

03

Conditions studied

  • Hodgkin Lymphoma
  • Peripheral T Cell Lymphoma
  • Anaplastic Large Cell Lymphoma

Keywords

  • CD30-expression
  • sALCL
  • PTCL
  • cHL
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed cHL, sALCL, or other CD30-expressing PTCL
  • Previously treated with brentuximab vedotin containing regimen, with evidence of objective response, and subsequent disease progression or relapse after discontinuing treatment
  • Documentation of disease relapse or progression ≥6 months after the last dose of brentuximab vedotin
  • Fluorodeoxyglucose positron emission tomography- (FDG-PET) avid and bidimensional of at least 1.5 cm in longest axis as documented by radiographic technique
  • (ECOG) performance status of less than or equal to 2
  • Must not be pregnant and, if of childbearing or fathering potential, must agree to use 2 effective methods during study and for 6 months following last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Previously discontinued brentuximab vedotin due to any Grade 3 or higher toxicity
  • Existing Grade 2 or higher peripheral neuropathy
  • Previously to treatment with brentuximab vedotin
  • History of a cerebral vascular event, unstable angina, or myocardial infarction within 6 months prior to first dose
  • History of another within 3 years before first dose of study drug or any evidence of residual disease from previously diagnosed malignancy
  • Acute or chronic graft-versus-host-disease (GvHD) or receiving therapy as treatment for or prophylaxis agent against GvHD
  • Active cerebral/meningeal disease
  • History of progressive multifocal leukoencephalopathy (PML)
  • Active uncontrolled Grade 3 (per v5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to first dose of study drug
  • Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 4 weeks prior to first dose of study drug, unless underlying disease has progressed on treatment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Brentuximab vedotin

    Drug: brentuximab vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per BICR According to Modified Lugano Response Criteria

    Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to the modified Lugano Criteria for Response Assessment (Cheson 2014) based on BICR

    Time frame: Up to 18.3 months

  2. Number of Participants With Adverse Events

    An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.

    Time frame: Up to 36 months

  3. Number of Participants With Laboratory Abnormalities

    Laboratory data was summarized by the worst post-baseline grade, by NCI CTCAE v5.0 or higher for each parameter.

    Time frame: Up to 36 months

Secondary outcomes

  1. Duration of Response (DOR) Per BICR According to Modified Lugano Response Criteria

    Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR), according to the Modified Lugano Criteria for Response Assessment (Cheson 2007), to the first documentation of objective tumor progression or to death due to any cause, whichever comes first.

    Time frame: Up to 17.1 months

  2. Progression-free Survival (PFS) Per BICR According to Modified Lugano Response Criteria

    PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.

    Time frame: up to 18.3 months

  3. Overall Survival (OS)

    OS is defined as the time from date of enrollment to date of death due to any cause.

    Time frame: Up to 35.8 months

  4. Rate of Complete Response (CR) Per BICR According to Modified Lugano Response Criteria

    CR rate is defined as the percentage of participants with CR according to the modified Lugano Criteria for Response Assessment (Cheson 2014)

    Time frame: Up to 18.3 months

  5. ORR Per Investigator Assessment According to Modified Lugano Response Criteria

    Objective Response Rate (ORR) is defined as the percentage of participants with CR or PR according to the modified Lugano Criteria for Response Assessment (Cheson 2014) based on investigator assessment

    Time frame: Up to 18.3 months

  6. DOR Per Investigator Assessment According to Modified Lugano Response Criteria

    Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR), according to the Modified Lugano Criteria for Response Assessment (Cheson 2007), to the first documentation of objective tumor progression or to death due to any cause, whichever comes first.

    Time frame: Up to 17.1 months

  7. Progression-free Survival Per Investigator Assessment According to Modified Lugano Response Criteria

    PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.

    Time frame: Up to 18.3 months

  8. Rate of Complete Response Per Investigator Assessment According to Modified Lugano Response Criteria

    CR rate is defined as the percentage of participants with CR according to the Modified Lugano Criteria for Response Assessment (Cheson 2014).

    Time frame: Up to 18.3 months

  9. ORR Per BICR According to Lugano Response Criteria

    ORR is defined as the percentage of participants with CR or PR, assessed according to Lugano Criteria for Response Assessment (Cheson 2014)

    Time frame: Up to 18.3 months

07

Results

Posted Oct 13, 2023

Participant flow

Participant flow — Overall Study
MilestoneClassic Hodgkin LymphomaPTCL
Started66
Completed00
Not completed66
Withdrew: Study closure by sponsor22
Withdrew: Withdrawal by subject22
Withdrew: Lost to follow-up20
Withdrew: Death02

Outcome measures

PrimaryObjective Response Rate (ORR) Per BICR According to Modified Lugano Response Criteria

Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to the modified Lugano Criteria for Response Assessment (Cheson 2014) based on BICR

Time frame:
Up to 18.3 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per BICR According to Modified Lugano Response Criteria
percentage of participantsClassic Hodgkin LymphomaPTCL
Objective Response Rate (ORR) Per BICR According to Modified Lugano Response Criteria40.0 (5.3 to 85.3)83.3 (35.9 to 99.6)
PrimaryNumber of Participants With Adverse Events

An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.

Time frame:
Up to 36 months
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsClassic Hodgkin LymphomaPTCL
Any TEAE56
Treatment-related TEAE45
Any Treatment-Emergent SAE02
Discontinuation of treatment due to TEAE13
Discontinuation of treatment due to treatment-related TEAE13
TEAE leading to death00
SecondaryDuration of Response (DOR) Per BICR According to Modified Lugano Response Criteria

Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR), according to the Modified Lugano Criteria for Response Assessment (Cheson 2007), to the first documentation of objective tumor progression or to death due to any cause, whichever comes first.

Time frame:
Up to 17.1 months
Reported as:
Median · months
Duration of Response (DOR) Per BICR According to Modified Lugano Response Criteria
monthsClassic Hodgkin LymphomaPTCL
Duration of Response (DOR) Per BICR According to Modified Lugano Response CriteriaNA (NA to NA)NA (2.9 to NA)
PrimaryNumber of Participants With Laboratory Abnormalities

Laboratory data was summarized by the worst post-baseline grade, by NCI CTCAE v5.0 or higher for each parameter.

Time frame:
Up to 36 months
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsClassic Hodgkin LymphomaPTCL
Hemoglobin Low, Grade 1-232
Hemoglobin Low, Grade 300
Hemoglobin Low, Grade 400
Leukocytes Low, Grade 1-212
Leukocytes Low, Grade 300
Leukocytes Low, Grade 400
Lymphocytes Low, Grade 1-211
Lymphocytes Low, Grade 301
Lymphocytes Low, Grade 400
Neutrophils Low, Grade 1-202
Neutrophils Low, Grade 301
Neutrophils Low, Grade 400
Platelets Low, Grade 1-212
Platelets Low, Grade 300
Platelets Low, Grade 400
Alanine Aminotransferase High, Grade 1-210
Alanine Aminotransferase High, Grade 300
Alanine Aminotransferase High, Grade 400
Albumin Low, Grade 1-203
Albumin Low, Grade 300
Albumin Low, Grade 400
Alkaline Phosphatase High, Grade 1-213
Alkaline Phosphatase High, Grade 300
Alkaline Phosphatase High, Grade 400
Aspartate Aminotransferase High, Grade 1-232
Aspartate Aminotransferase High, Grade 300
Aspartate Aminotransferase High, Grade 400
Bilirubin High, Grade 1-201
Bilirubin High, Grade 300
Bilirubin High, Grade 400
Calcium Corrected for Albumin Low, Grade 1-201
Calcium Corrected for Albumin Low, Grade 300
Calcium Corrected for Albumin Low, Grade 400
Creatinine High, Grade 1-211
Creatinine High, Grade 301
Creatinine High, Grade 400
Lactate Dehydrogenase High, Grade 1-234
Lactate Dehydrogenase High, Grade 300
Lactate Dehydrogenase High, Grade 400
Potassium Low, Grade 1-212
Potassium Low, Grade 301
Potassium Low, Grade 400
Sodium High, Grade 1-201
Sodium High, Grade 300
Sodium High, Grade 400
Sodium Low, Grade 1-231
Sodium Low, Grade 300
Sodium Low, Grade 400
SecondaryProgression-free Survival (PFS) Per BICR According to Modified Lugano Response Criteria

PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.

Time frame:
up to 18.3 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per BICR According to Modified Lugano Response Criteria
MonthsClassic Hodgkin LymphomaPTCL
Progression-free Survival (PFS) Per BICR According to Modified Lugano Response CriteriaNA (1.3 to NA)NA (1.1 to NA)
SecondaryOverall Survival (OS)

OS is defined as the time from date of enrollment to date of death due to any cause.

Time frame:
Up to 35.8 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsClassic Hodgkin LymphomaPTCL
Overall Survival (OS)NA (NA to NA)NA (1.1 to NA)
SecondaryRate of Complete Response (CR) Per BICR According to Modified Lugano Response Criteria

CR rate is defined as the percentage of participants with CR according to the modified Lugano Criteria for Response Assessment (Cheson 2014)

Time frame:
Up to 18.3 months
Reported as:
Number · Percentage of Participants
Rate of Complete Response (CR) Per BICR According to Modified Lugano Response Criteria
Percentage of ParticipantsClassic Hodgkin LymphomaPTCL
Rate of Complete Response (CR) Per BICR According to Modified Lugano Response Criteria20.0 (0.5 to 71.6)66.7 (22.3 to 95.7)
SecondaryORR Per Investigator Assessment According to Modified Lugano Response Criteria

Objective Response Rate (ORR) is defined as the percentage of participants with CR or PR according to the modified Lugano Criteria for Response Assessment (Cheson 2014) based on investigator assessment

Time frame:
Up to 18.3 months
Reported as:
Number · Percentage of Participants
ORR Per Investigator Assessment According to Modified Lugano Response Criteria
Percentage of ParticipantsClassic Hodgkin LymphomaPTCL
ORR Per Investigator Assessment According to Modified Lugano Response Criteria60.0 (14.7 to 94.7)83.3 (35.9 to 99.6)
SecondaryDOR Per Investigator Assessment According to Modified Lugano Response Criteria

Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR), according to the Modified Lugano Criteria for Response Assessment (Cheson 2007), to the first documentation of objective tumor progression or to death due to any cause, whichever comes first.

Time frame:
Up to 17.1 months
Reported as:
Median · Months
DOR Per Investigator Assessment According to Modified Lugano Response Criteria
MonthsClassic Hodgkin LymphomaPTCL
DOR Per Investigator Assessment According to Modified Lugano Response CriteriaNA (5.1 to NA)NA (7.2 to NA)
SecondaryProgression-free Survival Per Investigator Assessment According to Modified Lugano Response Criteria

PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.

Time frame:
Up to 18.3 months
Reported as:
Median · Months
Progression-free Survival Per Investigator Assessment According to Modified Lugano Response Criteria
MonthsClassic Hodgkin LymphomaPTCL
Progression-free Survival Per Investigator Assessment According to Modified Lugano Response Criteria6.5 (3.2 to NA)NA (1.1 to NA)
SecondaryRate of Complete Response Per Investigator Assessment According to Modified Lugano Response Criteria

CR rate is defined as the percentage of participants with CR according to the Modified Lugano Criteria for Response Assessment (Cheson 2014).

Time frame:
Up to 18.3 months
Reported as:
Number · Percentage of Participants
Rate of Complete Response Per Investigator Assessment According to Modified Lugano Response Criteria
Percentage of ParticipantsClassic Hodgkin LymphomaPTCL
Rate of Complete Response Per Investigator Assessment According to Modified Lugano Response Criteria40.0 (5.3 to 85.3)66.7 (22.3 to 95.7)
SecondaryORR Per BICR According to Lugano Response Criteria

ORR is defined as the percentage of participants with CR or PR, assessed according to Lugano Criteria for Response Assessment (Cheson 2014)

Time frame:
Up to 18.3 months
Reported as:
Number · Percentage of Participants
ORR Per BICR According to Lugano Response Criteria
Percentage of ParticipantsClassic Hodgkin LymphomaPTCL
ORR Per BICR According to Lugano Response Criteria60.0 (14.7 to 94.7)83.3 (35.9 to 99.6)

Adverse events

Collected over Non-serious Adverse Events, Serious Adverse Events, and All-Cause Mortality were followed for up to 36 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Classic Hodgkin Lymphoma0/6 (0%)0/5 (0%)5/5 (100%)
PTCL2/6 (33.3%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventClassic Hodgkin LymphomaPTCL
Gastroenteritis norovirusInfections and infestations0/51/6
Ankle fractureInjury, poisoning and procedural complications0/51/6
Most frequent other events
Showing 10 of 32
Most frequent other events
EventClassic Hodgkin LymphomaPTCL
Peripheral sensory neuropathyNervous system disorders1/54/6
NauseaGastrointestinal disorders2/51/6
NeutropeniaBlood and lymphatic system disorders0/52/6
FatigueGeneral disorders1/52/6
HyperglycaemiaMetabolism and nutrition disorders1/50/6
Back painMusculoskeletal and connective tissue disorders1/50/6
Neuropathy peripheralNervous system disorders1/50/6
ParaesthesiaNervous system disorders1/50/6
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/50/6
Abdominal painGastrointestinal disorders0/51/6

Baseline characteristics

The full analysis set includes participants who received at least one dose of study treatment.

Age, Categorical
Age, Categorical(Participants)Classic Hodgkin LymphomaPTCLTotal
<=18 years000
Between 18 and 65 years538
>=65 years033
Age, Continuous
Age, Continuous(Years)Classic Hodgkin LymphomaPTCLTotal
Median31 (28 to 55)63 (35 to 77)50 (28 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Classic Hodgkin LymphomaPTCLTotal
Female325
Male246
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Classic Hodgkin LymphomaPTCLTotal
Hispanic or Latino101
Not Hispanic or Latino4610
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Classic Hodgkin LymphomaPTCLTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American336
White235
More than one race000
Unknown or Not Reported000
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Classic Hodgkin LymphomaPTCLTotal
Grade 0325
Grade 1246
08

Study locations

19 sites
  • Pacific Cancer Medical Center
    Anaheim, California 92801, United States
  • SCL Health Good Samaritan Medical Center Cancer Centers of Colorado
    Lafayette, Colorado 80026, United States
  • Memorial Cancer Institute
    Pembroke Pines, Florida 33028, United States
  • Northwest Oncology and Hematology/AMITA
    Elk Grove Village, Illinois 60007, United States
  • Cardinal Bernardin Cancer Center / Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana 70112, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48201, United States
  • Saint Louis University
    Saint Louis, Missouri 63103, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Summit Medical Group
    Florham Park, New Jersey 07932, United States
  • Medical University of South Carolina/Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Texas Oncology - Fort Worth
    Dallas, Texas 75246, United States
  • Texas Oncology - Fort Worth 12th Avenue
    Fort Worth, Texas 76104, United States
  • The Center for Cancer and Blood Disorders: Fortworth
    Fort Worth, Texas 76104, United States
  • MD Anderson Cancer Center / University of Texas
    Houston, Texas 77030-4095, United States
  • Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • Texas Oncology - San Antonio Medical Center
    San Antonio, Texas 78240, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Nov 2022, 36 months.

Results were first posted in Oct 2023, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2019
First posted
May 13, 2019
StartActual
Oct 28, 2019
Primary completionActual
Nov 6, 2022
CompletionActual
Nov 6, 2022
Results first posted
Oct 13, 2023
Last update
Oct 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03947255
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
May 13, 2019
Start date
Oct 28, 2019
Primary completion
Nov 6, 2022
Completion
Nov 6, 2022
Results posted
Oct 13, 2023
Last update
Oct 13, 2023

Study contacts

Dominic Lai, MD
study director · Seagen Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion